Bidding 12-14 May 2026, price band ₹41–43, lot 3000 shares.
GMP last updated: 19 May 2026, 9:31 AM IST
| Date | GMP (₹) | Est. Listing Price (₹) | Est. Listing Gain |
|---|---|---|---|
| 18 May | ₹15 | ₹58 | 34.88% |
| 17 May | ₹15 | ₹58 | 34.88% |
| 16 May | ₹20 | ₹63 | 46.51% |
| 15 May | ₹20 | ₹63 | 46.51% |
| 14 May | ₹20 | ₹63 | 46.51% |
| 13 May | ₹15 | ₹58 | 34.88% |
| 12 May | ₹25 | ₹68 | 58.14% |
| 11 May | ₹18 | ₹61 | 41.86% |
| 10 May | ₹17 | ₹60 | 39.53% |
| 9 May | ₹16 | ₹59 | 37.21% |
| 8 May | ₹15 | ₹58 | 34.88% |
| 7 May | ₹8 | ₹51 | 18.60% |
| 6 May | ₹0 | ₹43 | 0.00% |
After allotment
| Category | Times | Est. Allotment Chances* |
|---|---|---|
| HNIs (Total) | 1661.37🔥 | <0.01% |
| bHNI | 1995.14🔥 | <0.01% |
| sHNI | 993.83🔥 | 0.10% |
| QIBs | 180.22🔥 | - |
| Retail | 876.55🔥 | 0.11% |
| Total | 838.33🔥 | - |
*Rough estimate: 1 ÷ times subscribed. Retail and HNI allotment is by lottery, so actual odds depend on the number of applications.
Goldline Pharmaceutical Limited is a pharmaceutical marketing and distribution company that sells products under the “Goldline” brand in India. The company operates through five product categories: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife and Goldline Wellness, which cater to therapeutic areas such as cardiology, diabetology, orthopaedics, paediatrics, critical care and supportive cancer care. The company does not manufacture products in-house and instead follows a third-party manufacturing model through contract manufacturers that comply with regulatory and quality standards. Its revenue is primarily generated from the sale and distribution of pharmaceutical products and related material supply and procurement support services. Goldline focuses on expanding its product portfolio and market reach through marketing and distribution activities while leveraging external manufacturers for production and formulation support.